History of erythema nodosum if characterized by a desquamating rash while taking thalidomide, pomalidomide, or similar drugs
The development of erythema nodosum as characterized by desquamating rash while taking thalidomide or similar drugs
Known prior development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
History of hypersensitivity reactions attributed to thalidomide, lenalidomide, or pomalidomide, including prior development of erythema nodosum if characterized by a desquamating rash while taking thalidomide, lenalidomide, or pomalidomide
The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
Known hypersensitivity to thalidomide, lenalidomide or pomalidomide including prior development of erythema nodosum if characterized by a desquamating rash while taking thalidomide, lenalidomide or pomalidomide
The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
Patients must not have prior history of desquamating rash from thalidomide at time of study entry
The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
Known prior clinically relevant hypersensitivity reaction to thalidomide, including the development of erythema nodosum if characterized by a desquamating rash
The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide, lenalidomide or similar drugs
The development of erythema multiforme if characterized by a desquamating rash while taking thalidomide or similar drugs
The development of erythema nodosum if characterized by a desquamating rash while taking lenalidomide
The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide, lenalidomide or similar drugs
History of erythema nodosum, characterized by a desquamating rash while taking thalidomide or similar drugs
The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide, lenalidomide or similar drugs in the past
The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
Known hypersensitivity to thalidomide, lenalidomide or rituximab; including the development of erythema nodosum if characterized by a desquamating rash while taking thalidomide
The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
History of erythema nodosum characterized by desquamating rash while taking thalidomide or similar drugs.
The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
Development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
Patient developed erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or lenalidomide drugs
The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
History of Stevens-Johnson syndrome characterized by a desquamating rash while taking thalidomide or similar drugs.
The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
